Literature DB >> 9124459

Cutaneous vasodilation during dorsal column stimulation is mediated by dorsal roots and CGRP.

J E Croom1, R D Foreman, M J Chandler, K W Barron.   

Abstract

Dorsal column stimulation (DCS) is used clinically to provide pain relief from peripheral vascular disease and has the benefit of increasing cutaneous blood flow to the affected lower extremities. The purpose of this study was to examine the role of dorsal roots, calcitonin gene-related peptide (CGRP), and substance P in the cutaneous vasodilation induced by DCS. Male rats were anesthetized with pentobarbital sodium (60 mg/kg ip). A unipolar ball electrode was placed unilaterally on the spinal cord at the L1-L2 spinal segment. Blood flow was recorded in each hindpaw foot pad with laser Doppler flowmeters. Blood flow responses were assessed during 1 min of DCS (either 0.2 mA subdural or 0.6 mA epidural at 50 Hz, 0.2-ms pulse duration). Dorsal rhizotomy of L3-L5 (n = 5) abolished the cutaneous vasodilation to subdural DCS, whereas removal of T10-T12 (n = 5) and T13-L2 dorsal roots (n = 5) did not attenuate the DCS-induced vasodilation. The CGRP antagonist, CGRP-(8-37) (2.6 mg/kg iv, n = 7), eliminated the epidural DCS-induced vasodilation, whereas the substance P receptor antagonist, CP-96345 (1 mg/kg iv, n = 6), had no effect. In summary, L3-L5 dorsal roots and CGRP are essential for the DCS-induced vasodilation. We propose that DCS antidromically activates afferent fibers in the dorsal roots, thus causing peripheral release of CGRP, which produces cutaneous vasodilation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9124459     DOI: 10.1152/ajpheart.1997.272.2.H950

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  17 in total

Review 1.  Contemporary insights into painful diabetic neuropathy and treatment with spinal cord stimulation.

Authors:  Kai McGreevy; Kayode A Williams
Journal:  Curr Pain Headache Rep       Date:  2012-02

2.  Effects of stimulation of the trigeminal caudal nucleus on microvascular permeability in the eye in normal and capsaicin-treated rats.

Authors:  Z S Tolochko
Journal:  Neurosci Behav Physiol       Date:  2003-06

Review 3.  Uncommon areas of electrical stimulation for pain relief.

Authors:  L Lou
Journal:  Curr Rev Pain       Date:  2000

Review 4.  Stimulation methods for neuropathic pain control.

Authors:  M P Stojanovic
Journal:  Curr Pain Headache Rep       Date:  2001-04

5.  Effect of indomethacin on capillary growth and microvasculature in chronically stimulated rat skeletal muscles.

Authors:  S C Pearce; O Hudlická; M D Brown
Journal:  J Physiol       Date:  2000-07-15       Impact factor: 5.182

6.  Extracellular signal-regulated kinase (ERK) and protein kinase B (AKT) pathways involved in spinal cord stimulation (SCS)-induced vasodilation.

Authors:  Mingyuan Wu; Naoka Komori; Chao Qin; Jay P Farber; Bengt Linderoth; Robert D Foreman
Journal:  Brain Res       Date:  2008-01-12       Impact factor: 3.252

7.  Femoral vascular conductance and peroneal muscle sympathetic nerve activity responses to acute epidural spinal cord stimulation in humans.

Authors:  Seth W Holwerda; Marshall T Holland; Chandan G Reddy; Gary L Pierce
Journal:  Exp Physiol       Date:  2018-05-05       Impact factor: 2.969

Review 8.  And yet it moves: Recovery of volitional control after spinal cord injury.

Authors:  G Taccola; D Sayenko; P Gad; Y Gerasimenko; V R Edgerton
Journal:  Prog Neurobiol       Date:  2017-11-02       Impact factor: 11.685

Review 9.  Putative mechanisms behind effects of spinal cord stimulation on vascular diseases: a review of experimental studies.

Authors:  Mingyuan Wu; Bengt Linderoth; Robert D Foreman
Journal:  Auton Neurosci       Date:  2008-02-29       Impact factor: 3.145

10.  Roles of peripheral terminals of transient receptor potential vanilloid-1 containing sensory fibers in spinal cord stimulation-induced peripheral vasodilation.

Authors:  Mingyuan Wu; Naoka Komori; Chao Qin; Jay P Farber; Bengt Linderoth; Robert D Foreman
Journal:  Brain Res       Date:  2007-04-30       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.